DPDIMP#1-trial: Impact of DPYD gene test on the safety and efficacy of fluoropyrimidine therapy

Status

Completed

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518448-20-00

Enrollment

1000

Registered

2024-10-29

Start date

2019-10-17

Completion date

2025-03-17

Last updated

2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer, Colon cancer

Brief summary

The concentrations of fluorouracil, tegafur, and capecitabine and their metabolites and pharmacokinetic variables in plasma and fingertip capillary blood samples.

Interventions

DRUGTeysuno 15 mg/4.35 mg/11.8 mg hard capsules

DRUGCapecitabine Orion 150 mg kalvopäällysteiset tabletit

DRUGFluorouracil Accord 50 mg/ml injektio-/infuusioneste

DRUGliuos

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The concentrations of fluorouracil, tegafur, and capecitabine and their metabolites and pharmacokinetic variables in plasma and fingertip capillary blood samples.	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026